FDA is publishing interim acceptable intake levels of nitrosamine impurities in angiotensin II receptor blockers (ARBs) for manufacturers to use to ensure their finished drug products are safe for patients.
Questions and Answers: Impurities found in certain generic angiotensin II receptor blocker (ARB) products